Equities Analysts Offer Predictions for EHC FY2025 Earnings

Encompass Health Corporation (NYSE:EHC) – Research analysts at Zacks Research raised their FY2025 earnings estimates for shares of Encompass Health in a research note issued to investors on Wednesday, November 12th. Zacks Research analyst Team now forecasts that the company will earn $5.28 per share for the year, up from their previous estimate of $5.22. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Encompass Health’s current full-year earnings is $4.80 per share. Zacks Research also issued estimates for Encompass Health’s Q1 2026 earnings at $1.44 EPS, Q2 2026 earnings at $1.44 EPS, Q3 2026 earnings at $1.29 EPS, Q4 2026 earnings at $1.47 EPS, FY2026 earnings at $5.64 EPS, Q1 2027 earnings at $1.52 EPS, Q2 2027 earnings at $1.59 EPS, Q3 2027 earnings at $1.41 EPS and FY2027 earnings at $6.09 EPS.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Wednesday, March 16th. The company reported $0.93 EPS for the quarter. Encompass Health had a net margin of 9.33% and a return on equity of 18.19%. The firm had revenue of $136.30 million for the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS.

Several other analysts have also weighed in on the stock. Bank of America lifted their target price on shares of Encompass Health from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, September 10th. UBS Group upped their price objective on shares of Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, October 2nd. Weiss Ratings restated a “buy (b+)” rating on shares of Encompass Health in a research report on Wednesday, October 8th. Barclays upped their target price on shares of Encompass Health from $141.00 to $150.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Finally, KeyCorp raised their price target on Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Three investment analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. Based on data from MarketBeat.com, Encompass Health presently has an average rating of “Buy” and a consensus target price of $142.86.

Encompass Health Trading Up 0.2%

Shares of NYSE:EHC traded up $0.25 during mid-day trading on Thursday, hitting $115.05. The stock had a trading volume of 38,777 shares, compared to its average volume of 793,140. The company’s 50 day moving average is $123.08 and its 200-day moving average is $119.72. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. Encompass Health has a 12-month low of $87.85 and a 12-month high of $127.99. The company has a market cap of $11.58 billion, a PE ratio of 21.75, a P/E/G ratio of 2.20 and a beta of 0.91.

Institutional Investors Weigh In On Encompass Health

Several large investors have recently modified their holdings of the company. Xponance Inc. raised its stake in shares of Encompass Health by 1.6% during the 1st quarter. Xponance Inc. now owns 11,604 shares of the company’s stock worth $1,175,000 after buying an additional 187 shares in the last quarter. Apollon Wealth Management LLC grew its stake in shares of Encompass Health by 33.3% during the 1st quarter. Apollon Wealth Management LLC now owns 3,807 shares of the company’s stock valued at $386,000 after buying an additional 951 shares during the period. Tectonic Advisors LLC raised its holdings in shares of Encompass Health by 5.5% during the 1st quarter. Tectonic Advisors LLC now owns 6,489 shares of the company’s stock valued at $657,000 after buying an additional 337 shares during the period. Victory Capital Management Inc. boosted its holdings in Encompass Health by 8.0% in the first quarter. Victory Capital Management Inc. now owns 570,306 shares of the company’s stock valued at $57,761,000 after purchasing an additional 42,245 shares during the last quarter. Finally, Segall Bryant & Hamill LLC lifted its holdings in Encompass Health by 2.3% during the 1st quarter. Segall Bryant & Hamill LLC now owns 169,733 shares of the company’s stock worth $17,191,000 after buying an additional 3,839 shares during the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Patrick William Tuer sold 1,020 shares of the stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the transaction, the executive vice president directly owned 18,846 shares in the company, valued at approximately $2,329,177.14. This represents a 5.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is owned by company insiders.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Friday, January 2nd will be paid a $0.19 dividend. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $0.76 dividend on an annualized basis and a yield of 0.7%. Encompass Health’s dividend payout ratio (DPR) is currently 14.37%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.